HK1259455A1 - 抗原受體及其用途 - Google Patents

抗原受體及其用途

Info

Publication number: HK1259455A1
Authority: HK; Hong Kong
Prior art keywords: antigen receptors; receptors; antigen
Prior art date: 2015-10-07

Application number

HK19101861.3A

Other languages

English (en)

Inventor

Ralf Holger VOSS

Ugur Sahin

Matthias Theobald

Petra Simon

Matthias Birtel

Original Assignee

Biontech Cell & Gene Therapies Gmbh

Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-07

Filing date

2019-02-01

Publication date

2019-11-29

2019-02-01 Application filed by Biontech Cell & Gene Therapies Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh

2019-11-29 Publication of HK1259455A1 publication Critical patent/HK1259455A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Hematology (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

HK19101861.3A 2015-10-07 2019-02-01 抗原受體及其用途 HK1259455A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/EP2015/073156 WO2017059900A1 (en)	2015-10-07	2015-10-07	Antigen receptors and uses thereof
PCT/EP2016/073792 WO2017060300A1 (en)	2015-10-07	2016-10-05	Antigen receptors and uses thereof

Publications (1)

Publication Number	Publication Date
HK1259455A1 true HK1259455A1 (zh)	2019-11-29

Family

ID=54288785

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK18114447.0A HK1255312A1 (zh)	2015-10-07	2018-11-13	抗原受體及其用途
HK19101861.3A HK1259455A1 (zh)	2015-10-07	2019-02-01	抗原受體及其用途

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK18114447.0A HK1255312A1 (zh)	2015-10-07	2018-11-13	抗原受體及其用途

Country Status (20)

Country	Link
US (3)	US20180282390A1 (zh)
EP (2)	EP3617226A1 (zh)
JP (1)	JP6657393B2 (zh)
KR (1)	KR102084173B1 (zh)
CN (2)	CN115536752A (zh)
AU (1)	AU2016335217B2 (zh)
BR (1)	BR112018006006A2 (zh)
CA (1)	CA2998450C (zh)
DK (1)	DK3359563T3 (zh)
ES (1)	ES2748224T3 (zh)
HK (2)	HK1255312A1 (zh)
HU (1)	HUE046749T2 (zh)
IL (1)	IL258079B (zh)
MX (1)	MX378368B (zh)
NZ (1)	NZ740474A (zh)
PL (1)	PL3359563T3 (zh)
PT (1)	PT3359563T (zh)
SI (1)	SI3359563T1 (zh)
WO (2)	WO2017059900A1 (zh)
ZA (1)	ZA201801607B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018166589A1 (en) *	2017-03-15	2018-09-20	Biontech Cell & Gene Therapies Gmbh	Antigen receptors and uses thereof
CA3069842A1 (en)	2017-07-14	2019-01-17	Immatics Biotechnologies Gmbh	Improved dual specificity polypeptide molecule
EP3684817A4 (en)	2017-09-22	2021-06-09	Wuxi Biologics Ireland Limited.	NEW BIS SPECIFIC CD3 / CD19 POLYPEPTIDE COMPLEXES
CN111133003B (zh) *	2017-09-22	2024-01-12	上海药明生物技术有限公司	新型双特异性多肽复合物
CN107827959B (zh) *	2017-11-09	2018-10-30	杭州续缓生物科技有限公司	识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途
US20230192840A1 (en) *	2018-12-28	2023-06-22	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Antibody and use thereof
JP7261307B2 (ja) *	2019-01-28	2023-04-19	ウーシーバイオロジクスアイルランドリミテッド	新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体
WO2021190580A1 (en) *	2020-03-26	2021-09-30	Wuxi Biologics (Shanghai) Co., Ltd.	Bispecific polypeptide complexes, compositions, and methods of preparation and use
EP4334361A1 (en)	2021-05-05	2024-03-13	Immatics Biotechnologies GmbH	Antigen binding proteins specifically binding prame
WO2023215725A1 (en) *	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2024062138A1 (en)	2022-09-23	2024-03-28	Mnemo Therapeutics	Immune cells comprising a modified suv39h1 gene
WO2025052001A1 (en)	2023-09-07	2025-03-13	Mnemo Therapeutics	Methods and compositions for improving immune response
EP4520334A1 (en)	2023-09-07	2025-03-12	Mnemo Therapeutics	Methods and compositions for improving immune response

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
DE102006041455B4 (de)	2006-09-04	2011-07-28	Johannes-Gutenberg-Universität Mainz, 55122	Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
ES2518393T3 (es) *	2007-05-11	2014-11-05	Altor Bioscience Corporation	Moléculas de fusión y variantes de IL-15
MX340556B (es) *	2010-08-24	2016-07-14	Roche Glycart Ag	Anticuerpos biespecificos activables.
EA028804B1 (ru) *	2011-03-25	2018-01-31	Гленмарк Фармасьютикалс С.А.	Гетеродимерные иммуноглобулины
TWI622597B (zh) *	2011-03-28	2018-05-01	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2774160T3 (es) *	2012-02-13	2020-07-17	Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute	Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
AU2013312838B2 (en)	2012-09-04	2018-11-29	Cellectis	Multi-chain chimeric antigen receptor and uses thereof
WO2018166589A1 (en) *	2017-03-15	2018-09-20	Biontech Cell & Gene Therapies Gmbh	Antigen receptors and uses thereof

2015
- 2015-10-07 WO PCT/EP2015/073156 patent/WO2017059900A1/en active Application Filing
2016
- 2016-10-05 EP EP19187303.3A patent/EP3617226A1/en not_active Withdrawn
- 2016-10-05 HU HUE16777681A patent/HUE046749T2/hu unknown
- 2016-10-05 ES ES16777681T patent/ES2748224T3/es active Active
- 2016-10-05 US US15/765,926 patent/US20180282390A1/en not_active Abandoned
- 2016-10-05 CA CA2998450A patent/CA2998450C/en active Active
- 2016-10-05 CN CN202210717765.1A patent/CN115536752A/zh active Pending
- 2016-10-05 DK DK16777681.4T patent/DK3359563T3/da active
- 2016-10-05 PL PL16777681T patent/PL3359563T3/pl unknown
- 2016-10-05 EP EP16777681.4A patent/EP3359563B8/en active Active
- 2016-10-05 BR BR112018006006A patent/BR112018006006A2/pt active Search and Examination
- 2016-10-05 JP JP2018517521A patent/JP6657393B2/ja active Active
- 2016-10-05 NZ NZ740474A patent/NZ740474A/en unknown
- 2016-10-05 MX MX2018004121A patent/MX378368B/es unknown
- 2016-10-05 SI SI201630392T patent/SI3359563T1/sl unknown
- 2016-10-05 AU AU2016335217A patent/AU2016335217B2/en active Active
- 2016-10-05 PT PT167776814T patent/PT3359563T/pt unknown
- 2016-10-05 KR KR1020187010044A patent/KR102084173B1/ko active Active
- 2016-10-05 WO PCT/EP2016/073792 patent/WO2017060300A1/en active Application Filing
- 2016-10-05 CN CN201680058729.1A patent/CN108137673B/zh active Active
2018
- 2018-03-08 ZA ZA2018/01607A patent/ZA201801607B/en unknown
- 2018-03-13 IL IL258079A patent/IL258079B/en unknown
- 2018-11-13 HK HK18114447.0A patent/HK1255312A1/zh unknown
2019
- 2019-02-01 HK HK19101861.3A patent/HK1259455A1/zh unknown
2021
- 2021-09-18 US US17/478,906 patent/US20220033461A1/en not_active Abandoned
2022
- 2022-08-21 US US17/892,089 patent/US20230119334A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2018004121A (es)	2018-05-17
EP3617226A1 (en)	2020-03-04
NZ740474A (en)	2022-09-30
CN108137673B (zh)	2022-07-12
WO2017059900A1 (en)	2017-04-13
WO2017060300A1 (en)	2017-04-13
IL258079B (en)	2021-07-29
HUE046749T2 (hu)	2020-03-30
MX378368B (es)	2025-03-10
RU2018112327A (ru)	2019-11-07
US20180282390A1 (en)	2018-10-04
EP3359563B8 (en)	2019-10-02
ES2748224T3 (es)	2020-03-16
EP3359563B1 (en)	2019-07-31
KR20180057648A (ko)	2018-05-30
PL3359563T3 (pl)	2020-03-31
AU2016335217A8 (en)	2018-04-12
EP3359563A1 (en)	2018-08-15
AU2016335217A1 (en)	2018-03-29
KR102084173B1 (ko)	2020-03-03
SI3359563T1 (sl)	2019-11-29
PT3359563T (pt)	2019-10-18
BR112018006006A2 (pt)	2018-10-30
CA2998450C (en)	2020-06-23
US20230119334A1 (en)	2023-04-20
CN108137673A (zh)	2018-06-08
JP6657393B2 (ja)	2020-03-04
RU2018112327A3 (zh)	2019-11-12
HK1255312A1 (zh)	2019-08-16
CN115536752A (zh)	2022-12-30
ZA201801607B (en)	2020-11-25
US20220033461A1 (en)	2022-02-03
AU2016335217B2 (en)	2021-04-29
JP2018530331A (ja)	2018-10-18
DK3359563T3 (da)	2019-09-30
IL258079A (en)	2018-05-31
CA2998450A1 (en)	2017-04-13

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
HK1255067A1 (zh)	2019-08-02	抗c10orf54抗體及其用途
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
HK1243440A1 (zh)	2018-07-13	抗白細胞介素-33抗體及其用途
ZA201800536B (en)	2019-07-31	Il-8-binding antibodies and uses thereof
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
HK1259455A1 (zh)	2019-11-29	抗原受體及其用途
IL247407B (en)	2020-05-31	Antibodies against egfrviii and their uses
IL251001B (en)	2021-04-29	Anti-il-25 antibodies and their uses
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
RS62912B1 (sr)	2022-03-31	Antihumana-her3 antitela i njihova primena
HK1254240A1 (zh)	2019-07-12	抗羥腐胺賴氨酸抗體及其用途
ZA201905441B (en)	2020-11-25	Antigen receptors and uses thereof